DEBx Medical B.V.
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
Recognized for Advancing Global Wound Care Through Innovation and Efficacy
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the 16th Abu Dhabi Wound Care Conference.
Presented during the Opening Ceremony at ADNEC, this recognition by the International Interprofessional Wound Care Group (IIWCG) honors excellence in wound care and spotlights breakthroughs redefining standards in chronic wound management through innovation and efficacy.
It is not only an honor for DEBx Medical—it’s a tribute to the clinical judgment of many clinicians who continue to put DEBRICHEM® into practice and improve outcomes, even in the most challenging cases.
DEBRICHEM®: One Application. First Line. Debridement Solution.
With just one 60-second application, DEBRICHEM® eradicates devitalized tissue, infection, and biofilm from chronic wounds, key barriers that prevent healing from progressing.
For clinicians, it offers:
- Rapid, targeted action, reopening the pathway to healing
- An easy-to-use approach for multifactorial wounds
- A results-driven practical solution in high-pressure settings
For healthcare systems and patients, it enables:
- Fewer interventions and lower resource use
- Better patient compliance across different wound etiologies
- Potential reduced reliance on antibiotics, helping to counter antimicrobial resistance
- A meaningful step forward in the fight against amputations
Backed by scientific evidence, DEBRICHEM® supports clinicians in both advanced hospital settings and remote or resource-limited environments.
In a time when healthcare efficiency and antimicrobial resistance are pressing global concerns, innovation like DEBRICHEM® is not just valuable, it’s vital.
“It’s a moment of shared pride and purpose. This recognition by the IIWCG is an incredible honor, not just for DEBx Medical, but for every clinician and patient who places their trust in innovation. DEBRICHEM® was developed to meet a critical gap in chronic wound care. This award validates the real-world impact our team strives for every day: restoring dignity, preserving limbs, improving lives.”— Bert Quint, CEO, DEBx Medical
The award underscores DEBx Medical’s commitment to advancing wound care that prioritizes patient progress above all.
About DEBx Medical
DEBx Medical is a medical technology business dedicated to revolutionizing the management of chronic wounds. It focuses on delivering disruptive and efficient wound care treatments that are easy to use and implement in daily clinical practice: DEBRICHEM® - Innovating The Future of Wound Care
For inquiries:
DEBx Medical: Chandrita Jaisinghani, press@debx-medical.com, +31 85 0878096
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma18.7.2025 18:30:00 CEST | Press release
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
SpringWorks Therapeutics, Inc.18.7.2025 17:30:40 CEST | Press release
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Photocat A/S18.7.2025 17:00:00 CEST | Press release
PHOTOCAT has today applied for a transfer of its trading venue from Nasdaq First North Growth Market to Spotlight Stock Market.
Golden Ocean Group Limited18.7.2025 16:30:00 CEST | Press release
GOGL – Notice of Special General Meeting
Kapitalforeningen SDG Invest18.7.2025 16:06:31 CEST | Pressemeddelelse
Kapitalforeningen SDG Invest - Opdateret prospekt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom